Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics
company, announced results today from its Phase I extension study with
ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of
advanced solid tumors with liver involvement. The data
are being presented in a poster titled "Open-Label Extension Study of
the RNAi Therapeutic ALN-VSP02 in Cancer Patients Responding to
Therapy," in the Development Therapeutics - Experimental Therapeutics
poster session being held Monday, June 4, 2012 from 8:00 a.m. to 12:00
p.m. CDT. Overall, the results demonstrated disease control lasting more
than six months in the majority of patients treated on the extension
study, including a complete response (CR) in an endometrial cancer
patient who had multiple liver metastases. In this study, chronic dosing
of up to 23 months with ALN-VSP was found to be generally safe and well
tolerated.
"We are very encouraged with the continued positive data from our
ALN-VSP Phase I clinical trial and extension study. These data include
safety and tolerability of multiple doses of ALN-VSP, as well as
evidence for anti-tumor activity in this very advanced, heavily
pre-treated cancer patient population. We have seen multiple patients
achieve stable disease or better, including a patient with endometrial
cancer metastatic to the liver who has achieved a complete response,"
said Jared Gollob, M.D., Senior Director of Clinical Research at
Alnylam. "Results from the extension study also give us increased
confidence in long-term chronic dosing with RNAi therapeutics delivered
via LNPs, as patients have received drug twice a month for up to nearly
two years, and approximately 11 months on average. We look forward to
partnering this program to further advance the clinical development of
ALN-VSP as we believe the evidence of anti-tumor activity warrants Phase
II testing."